Deep vein thrombosis · people requiring prevention of venous thromboembolism
Fondaparinux probably leads to lower total DVT compared with placebo (moderate certainty).
1 finding from 1 review
Proximal DVT · people requiring prevention of venous thromboembolism
Fondaparinux probably leads to lower proximal DVT compared with placebo (moderate certainty).
1 finding from 1 review
Total PE · people requiring prevention of venous thromboembolism
Fondaparinux leads to lower total PE compared with placebo (high certainty).
1 finding from 1 review
Major bleeding · people requiring prevention of venous thromboembolism
Fondaparinux probably leads to higher major bleeding compared with placebo (moderate certainty).
1 finding from 1 review
All causes of death · people requiring prevention of venous thromboembolism
Fondaparinux showed no clear difference in all causes of death compared with placebo (moderate certainty).
1 finding from 1 review
Pain‐free walking distance · people with symptomatic intermittent claudication
1 finding from 1 review
Change in maximum walking distance (MWD) · people with symptomatic intermittent claudication
1 finding from 1 review
Final value MWD · people with symptomatic intermittent claudication
1 finding from 1 review
Adverse effects · people with symptomatic intermittent claudication
It is very uncertain whether padma 28 changes adverse effects compared with placebo (very low certainty).
1 finding from 1 review
Ankle brachial index · people with symptomatic intermittent claudication
1 finding from 1 review
ABI ‐ change from baseline · people with symptomatic intermittent claudication
1 finding from 1 review
Total VTE · 17,802 patients with low to normal levels of low density lipoprotein (LDL) cholesterol (< 130 mg/dL)
Statin probably leads to lower all cases of VTE compared with placebo (moderate certainty).
1 finding from 1 review
Pulmonary embolism · 17,802 patients with low to normal levels of low density lipoprotein (LDL) cholesterol (< 130 mg/dL)
1 finding from 1 review
Deep vein thrombosis · 17,802 patients with low to normal levels of low density lipoprotein (LDL) cholesterol (< 130 mg/dL)
1 finding from 1 review
Any MI · 17,802 patients with low to normal levels of low density lipoprotein (LDL) cholesterol (< 130 mg/dL)
Statin probably leads to lower any MI compared with placebo (moderate certainty).
1 finding from 1 review
Stroke · 17,802 patients with low to normal levels of low density lipoprotein (LDL) cholesterol (< 130 mg/dL)
Statin probably leads to lower any stroke compared with placebo (moderate certainty).
1 finding from 1 review
Death · 17,802 patients with low to normal levels of low density lipoprotein (LDL) cholesterol (< 130 mg/dL)
Statin probably leads to lower death compared with placebo (moderate certainty).
1 finding from 1 review
Any serious adverse event · 17,802 patients with low to normal levels of low density lipoprotein (LDL) cholesterol (< 130 mg/dL)
Statin showed no clear difference in any serious adverse event compared with placebo (moderate certainty).
1 finding from 1 review